Are there any clinical scenarios in which you would treat BRCA mutated HER2 negative metastatic breast cancer with a PARP inhibitor in combination with carboplatin?
Do any studies support this rationale? Does the presence of a somatic vs germline BRCA mutation impact your decision?
Thank you, Dr. @Banu Arun. If I can ask her...